Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of SI-6603 in Patients with Lumbar Disc Herniation

Trial Profile

A Phase III Study of SI-6603 in Patients with Lumbar Disc Herniation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Condoliase (Primary)
  • Indications Intervertebral disc displacement
  • Focus Registrational; Therapeutic Use
  • Sponsors Seikagaku Corporation
  • Most Recent Events

    • 23 Mar 2018 Based on the data from this trial, the Japanese Ministry of Health, Labour and Welfare ("MHLW") has approved the New Drug Application ("NDA") of HERNICORE 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation.
    • 18 Sep 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan
    • 05 Jun 2014 According to the Seikagaku Corporation media release, results from this trial presented at the 41st Annual Meeting of the International Society for the Study of the Lumbar Spine on 4 June 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top